Measuring platelet aggregation ability using the PATI can help clinicians understand the underlying pathology and guide antithrombotic treatment choices in patients with recurrent stent thrombosis.
Answers are grounded in this paper and cite their sources.
PATI monitoring may inform antithrombotic choices in recurrent stent thrombosis; hypothesis-generating from one case and requires prospective validation.
An 86-year-old man successfully underwent percutaneous coronary intervention (PCI), in which a drug-coated stent (DCS) was placed in the left anterior descending coronary artery. However, stent thrombosis occurred twice after eight and two months. After the second admission, the patient was tested for platelet aggregation activity using the platelet aggregation threshold index (PATI), and insufficient inhibition of platelet aggregation was observed. The patient's PATI improved to a satisfactory level using oral anticoagulants. At the six-month follow-up, clinical events were observed. Measuring the platelet aggregation ability can help clinicians understand the pathology of patients and determine treatment choices.
No takes yet. Share an insight, caveat, or question.
Hirano et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: